AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Hollywood Private Hospital in Perth has given Ethics Committee approval.
- With this development, Hollowood Private Hospital becomes 2nd Australian site for RAD 204 Phase 1 trial.
- Recruitment for the trial would commence at Princess Alexandra Hospital in Brisbane.
- The trial is designed for patients with PD-L1-positive non-small cell lung cancer (NSCLC).
Radiopharm Theranostics Limited (ASX: RAD) would be opening a second site for its lung cancer trial.
As per the latest company update, Hollywood Private Hospital in Perth, Western Australia, has granted Human Research Ethics Committee (HREC) approval. With this development, Hollywood Private Hospital will become the second site in Australia for RAD 204 Phase 1 therapeutic study, which is focused on PD-L1-positive non-small cell lung cancer (NSCLC).
The addition of Perth site has resulted in widening of the geographic availability of the trial, and the recruitment is anticipated to advance accordingly. GenesisCare, a major oncology provider, is supporting the trial.
About the RAD 204 Phase 1 therapeutic study
The title of the study is –
Data source: Company update
It is the first-in-human dose escalation study of 177Lu-RAD 204, which aims at examining the efficacy and safety of 177Lu-RAD 204 in individuals with advanced NSCLC.
NSCLC is the most common type of lung cancer. Data from the American Cancer Society indicates that by the end of 2023, nearly 300,000 new lung cancer cases are estimated to be reported in the US, and 81% of this are expected to be diagnosed with NSCLC.
The trial is expected to open on 4 January 2024 at Princess Alexandra Hospital in Brisbane. In January 2024, the first patient is expected to be dosed.
This is what CEO and MD of RAD, Riccardo Canevari, commented on the latest development -
RAD shares traded at AU$0.071 midday on 27 December 2023.